Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL2502942 | 0.86 | TSHR (0.64) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Cyclohexane SCHEMBL6963396 | 0.83 | TSHR (0.82) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Cyclohexane SCHEMBL1659384 | 0.83 | TSHR (0.82) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL9744403 | 0.82 | TSHR (0.39) | TSHRHCAR2 | |
| Dioxane SCHEMBL1741544 | 0.81 | TSHR (0.70) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL21064874 | 0.80 | TSHR (1.00) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL19193 | 0.80 | — | — | |
| Ammonia Solution, Strong SCHEMBL5086843 | 0.77 | — | — | |
| SCHEMBL4431010 | 0.77 | TSHR (0.93) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Hydrochloric Acid SCHEMBL2107550 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880305-A1 | A CRYSTALLINE FORM OF 3- ( (L-VALYL) AMINO) -1-PROPANESULFONIC ACID | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-09-22 | — | — | EP | claimed |
| WO-2020098492-A1 | A CRYSTALLINE FORM OF 3- ( (L-VALYL) AMINO) -1-PROPANESULFONIC ACID | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2020-05-22 | — | — | WO | claimed |
| CN-115385918-A | Novel midazolam crystal form and preparation method thereof | 成都硕德药业有限公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-3880305-A1 | A CRYSTALLINE FORM OF 3- ( (L-VALYL) AMINO) -1-PROPANESULFONIC ACID | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020098492-A1 | A CRYSTALLINE FORM OF 3- ( (L-VALYL) AMINO) -1-PROPANESULFONIC ACID | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2020-05-22 | — | — | WO | disclosed |
| US-8916581-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| EP-1928882-B1 | (S)-N-METHYLNALTREXONE, PROCESS FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARM INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120136019-A1 | (S)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2450360-A2 | (S)-N-Methylnaltrexone | Progenics Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8003794-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100105911-A1 | (S)-N-methylnal trexone | ALBANY MOLECULAR RESEARCH, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7563899-B2 | (S)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1928882-A2 | (S)-N-METHYLNALTREXONE, PROCESS FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070265293-A1 | Opioid antagonists; lyophilization | PROGENICS PHARMACEUTICAIS, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2006127898-A2 | (S)-N-METHYLNALTREXONE, PROCESS FOR ITS SYNTHESIS AND ITS PHARMACEUTICAL USE | PROGENICS PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105911-A1 | (S)-N-methylnal trexone | TSNAX, MTX1, MTX2 | TSHR 1371/4885CHRM2 1075/4885CHRM4 629/4885 |
| US-20070265293-A1 | Opioid antagonists; lyophilization | OPRM1, OGFR, OPRL1 | TSHR 1691/4885CHRM2 449/4885CHRM4 243/4885 |
| US-20120136019-A1 | (S)-N-METHYLNALTREXONE | OPRM1, OPRL1, LPXN | TSHR 1450/4885CHRM2 131/4885CHRM4 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.